BPC-157 dosing & administration

Sikiric et al. · 2018

Demonstrated healing across multiple tissue types including tendon, ligament, muscle, and gut lining with no observed toxicity.

Seiwerth S, Milavic M, Vukojevic J, et al. · 2021

Accelerated wound closure and tissue regeneration in multiple animal models.

Chang et al. · 2011

Significantly improved tendon-to-bone healing in rat rotator cuff model.

Józwiak M, Bauer M, Kamysz W, Kleczkowska P · 2025

Open-access review (Pharmaceuticals 2025). BPC 157 has not been approved for use in standard medicine by the FDA or other regulators owing to the absence of sufficient and comprehensive clinical studies in humans. Most, if not all, studies are limited to small animal models (rats and mice); human studies are scarce — a retrospective 12-patient knee-pain study and a Phase I trial in 42 healthy volunteers started in 2015, for which submission of results was cancelled in 2016. No toxic dose has been determined in rat and dog toxicity studies. The review calls for in-depth analysis of the mechanism of action, describing it as still unknown.

Mateescu DM, Gavrilescu DM, Constantinescu FE, et al. · 2026

Open-access narrative review (Pharmaceutics 2026). BPC-157 has no approved formulation, no validated dosing regimen and no completed Phase II trial; early-phase Pliva investigations in inflammatory bowel disease (PL-10, PLD-116, PL14736) were not followed by Phase II or III trials, and available clinical data come from fewer than 30 subjects across three uncontrolled pilot studies. It was derived from a protein fragment in human gastric juice, and the GI tract is its most extensively characterised domain. It acts through multiple overlapping signalling pathways — documented targets include VEGFR2, Egr-1, the NO system and growth hormone receptor signalling — though no high-affinity receptor binding site has been identified and its molecular target remains formally unknown. Parenteral administration is described as the most pharmacokinetically reliable route; oral effects in rodents may reflect local mucosal action.

Vasireddi N, Hahamyan H, Salata MJ, et al. · 2025

Systematic review (HSS Journal 2025) of 36 studies (35 preclinical, 1 clinical). BPC-157 lacks US FDA approval and is banned in professional sports. In preclinical models it improved functional, structural and biomechanical outcomes in muscle, tendon, ligament and bone injuries; preclinical safety studies showed no adverse effects, and no clinical safety data were found. Adverse effects are possible due to unregulated manufacturing, contamination, or unknown clinical safety.

Yuan C, Demers A, Silva-Ortiz V, et al. · 2026

Open-access review (Int J Mol Sci 2026). Preclinical evidence shows BPC-157 supports angiogenesis, collagen synthesis and fibroblast activity, enhancing healing of muscle, tendon, ligament, bone and GI tissue. Human research is limited to small pilot studies. BPC-157 does not have FDA approval; complaints from unregulated use may reflect unregulated production and variable dosing, and standardisation and regulation of its preparation is described as necessary to prevent contamination.

Brcic L, Brcic I, Staresinic M, Novinscak T, Sikiric P, Seiwerth S · 2009

In rat crushed-muscle and transected muscle and tendon models, immunohistochemistry (VEGF, CD34, FVIII) showed adequately modulated angiogenesis in BPC 157-treated animals; the authors conclude BPC 157 stimulates angiogenesis by up-regulating VEGF expression, with no direct angiogenic effect on cell cultures.

Sikiric P, Seiwerth S, Grabarevic Z, et al. · 1997

In rat adjuvant arthritis (14 days to 1 year), BPC 157 (10 µg or 10 ng/kg i.p.) reduced lesion development and, given as therapy for established arthritis, produced a salutary effect after 2 weeks that persisted at 1 year; the authors conclude the data point to a special anti-inflammatory and mucosal-integrity protective effect.

Lee E, Padgett B · 2021

Retrospective chart review of 16 patients: 11 of 12 given intra-articular BPC 157 alone reported significant improvement in knee pain (14 of 16 overall including BPC 157 + TB4). No standardised outcome tools were used. The authors describe BPC 157 as a peptide with regenerative properties with the potential to repair tears and build cartilage.

Park JM, Lee HJ, Sikiric P, Hahm KB · 2020

Review (Curr Pharm Des 2020) describing, for the first time, the potential rescuing actions of BPC 157 against leaky gut syndrome after NSAID administration, via stabilised intestinal permeability and cytoprotection.

Matek D, Matek I, Japjec M, et al. · 2026

Open-access review (Pharmaceuticals 2026). Without any carrier, BPC 157 given systemically or locally combined beneficial effects on tendon, ligament and muscle injuries and junctional healing; in rat studies, across systemic (intraperitoneal, intragastric, drinking water) and local (cream) administration, it consistently demonstrated efficacy.